Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt No Debt
KIN's Cash-to-Debt is ranked higher than
75% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. KIN: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
KIN' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Interest Coverage No Debt
KIN's Interest Coverage is ranked higher than
68% of the 496 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. KIN: No Debt )
Ranked among companies with meaningful Interest Coverage only.
KIN' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 3
Altman Z-Score: 31.97
WACC vs ROIC
3.51%
-752.85%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
ROE % -37.38
KIN's ROE % is ranked higher than
51% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. KIN: -37.38 )
Ranked among companies with meaningful ROE % only.
KIN' s ROE % Range Over the Past 10 Years
Min: -37.38  Med: -32.19 Max: -13.34
Current: -37.38
-37.38
-13.34
ROA % -35.81
KIN's ROA % is ranked lower than
52% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. KIN: -35.81 )
Ranked among companies with meaningful ROA % only.
KIN' s ROA % Range Over the Past 10 Years
Min: -35.81  Med: -29.89 Max: -12.68
Current: -35.81
-35.81
-12.68
ROC (Joel Greenblatt) % -852.72
KIN's ROC (Joel Greenblatt) % is ranked lower than
62% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. KIN: -852.72 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
KIN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -70316.67  Med: -8371.98 Max: -852.72
Current: -852.72
-70316.67
-852.72
3-Year EBITDA Growth Rate 0.30
KIN's 3-Year EBITDA Growth Rate is ranked lower than
52% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. KIN: 0.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
KIN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0.15 Max: 0.3
Current: 0.3
0
0.3
GuruFocus has detected 1 Warning Sign with Kindred Biosciences Inc KIN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» KIN's 30-Y Financials

Financials (Next Earnings Date: 2018-03-01)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

KIN Guru Trades in Q4 2016

Jim Simons 351,600 sh (+6.03%)
John Rogers 3,940,859 sh (+2.76%)
Chuck Royce 148,000 sh (unchged)
Seth Klarman Sold Out
» More
Q1 2017

KIN Guru Trades in Q1 2017

Jim Simons 504,800 sh (+43.57%)
Chuck Royce 126,000 sh (-14.86%)
John Rogers 2,976,322 sh (-24.48%)
» More
Q2 2017

KIN Guru Trades in Q2 2017

Jim Simons 816,600 sh (+61.77%)
Chuck Royce 126,000 sh (unchged)
John Rogers 1,961,912 sh (-34.08%)
» More
Q3 2017

KIN Guru Trades in Q3 2017

John Rogers 2,340,123 sh (+19.28%)
Jim Simons 826,800 sh (+1.25%)
Chuck Royce 126,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with KIN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Rogers 2017-09-30 Add 19.28%0.03%$6.75 - $8.8 $ 7.40-2%2,340,123
John Rogers 2017-06-30 Reduce -34.08%0.11%Premium Member Access $9.25 $ 7.40-20%1,961,912
John Rogers 2017-06-30 Reduce -34.08%0.09%$6.65 - $9.25 $ 7.403%1,961,912
John Rogers 2017-03-31 Reduce -24.48%0.08%Premium Member Access $7.05 $ 7.405%2,976,322
John Rogers 2017-03-31 Reduce -24.48%0.05%$5.1 - $7.2 $ 7.4018%2,976,322
John Rogers 2016-12-31 Add 2.76%0.01%Premium Member Access $4.25 $ 7.4074%3,940,859
John Rogers 2016-12-31 Add 2.76%0.01%$3.96 - $5.49 $ 7.4053%3,940,859
Seth Klarman 2016-12-31 Sold Out 0.21%$3.96 - $5.49 $ 7.4053%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 541940    SIC: 742
Compare:NAS:SVRA, LSE:SLN, NAS:PPHM, XKRX:199800, ROCO:6575, XTAE:KMDA, ROCO:4167, XTAE:NTEC, NAS:SBPH, XPAR:TNG, HKSE:01035, TSE:4596, NAS:SBBP, TSX:ZYME, NAS:ECYT, NAS:VTVT, TSE:2395, NAS:ATHX, XKRX:005690, OTCPK:DGJI » details
Traded in other countries:17K.Germany,
Headquarter Location:USA
Kindred Biosciences Inc is a development-stage biopharmaceutical company. It is engaged in saving and improving the lives of pets. The Company's product candidates are SentiKind, KIND-010 and KIND-012.

Kindred Biosciences Inc is a development stage biopharmaceutical company developing pet care products. The company identifies compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses. Kindred Biosciences has a pipeline of novel drugs and biologics in development across various therapeutic classes. Its pipeline products include Mirataz, Zimeta, KIND-014, KIND-015, epoCat, Anti-Interleukin anibodeis, Anti-CD20, Anti-IgE, Anti-VEGF, Anti-TNF, and Checkpoint Inhibitors.

Ratios

vs
industry
vs
history
PB Ratio 2.24
KIN's PB Ratio is ranked higher than
70% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. KIN: 2.24 )
Ranked among companies with meaningful PB Ratio only.
KIN' s PB Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 3.05
Current: 2.24
0
3.05
EV-to-EBIT -4.42
KIN's EV-to-EBIT is ranked lower than
99.99% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. KIN: -4.42 )
Ranked among companies with meaningful EV-to-EBIT only.
KIN' s EV-to-EBIT Range Over the Past 10 Years
Min: -6.71  Med: 0 Max: 0
Current: -4.42
-6.71
0
EV-to-EBITDA -4.49
KIN's EV-to-EBITDA is ranked lower than
99.99% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. KIN: -4.49 )
Ranked among companies with meaningful EV-to-EBITDA only.
KIN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -6.77  Med: 0 Max: 0
Current: -4.49
-6.77
0
Current Ratio 23.99
KIN's Current Ratio is ranked higher than
97% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. KIN: 23.99 )
Ranked among companies with meaningful Current Ratio only.
KIN' s Current Ratio Range Over the Past 10 Years
Min: 10.63  Med: 28.27 Max: 45.03
Current: 23.99
10.63
45.03
Quick Ratio 23.99
KIN's Quick Ratio is ranked higher than
97% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. KIN: 23.99 )
Ranked among companies with meaningful Quick Ratio only.
KIN' s Quick Ratio Range Over the Past 10 Years
Min: 10.63  Med: 28.27 Max: 45.03
Current: 23.99
10.63
45.03

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -7.10
KIN's 3-Year Average Share Buyback Ratio is ranked higher than
60% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. KIN: -7.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
KIN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -7.1  Med: -3.55 Max: 0
Current: -7.1
-7.1
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 2.53
KIN's Price-to-Net-Cash is ranked higher than
84% of the 543 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. KIN: 2.53 )
Ranked among companies with meaningful Price-to-Net-Cash only.
KIN' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.97  Med: 1.66 Max: 5.19
Current: 2.53
0.97
5.19
Price-to-Net-Current-Asset-Value 2.49
KIN's Price-to-Net-Current-Asset-Value is ranked higher than
85% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 7.12 vs. KIN: 2.49 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
KIN' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.96  Med: 1.63 Max: 5.15
Current: 2.49
0.96
5.15
Price-to-Tangible-Book 2.24
KIN's Price-to-Tangible-Book is ranked higher than
76% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 5.09 vs. KIN: 2.24 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
KIN' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.88  Med: 1.57 Max: 5.14
Current: 2.24
0.88
5.14
Earnings Yield (Greenblatt) % -22.62
KIN's Earnings Yield (Greenblatt) % is ranked lower than
68% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. KIN: -22.62 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
KIN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -2000  Med: 0 Max: 0
Current: -22.62
-2000
0

More Statistics

EPS (TTM) $ -1.17
Beta0.19
Short Percentage of Float4.97%
52-Week Range $3.90 - 9.65
Shares Outstanding (Mil)28.16

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 10 20 34
EPS ($) -1.25 -1.18 -0.86 -0.36
EPS without NRI ($) -1.25 -1.18 -0.86 -0.36
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}